Biogen Reports New Spinraza Data In Atrophy Patients After Incomplete Response To Novartis' Treatment
Portfolio Pulse from Vandana Singh
Biogen Inc has announced new data on its drug Spinraza, showing improved motor function in infants and toddlers with spinal muscular atrophy (SMA) who had previously been treated with Novartis AG's gene therapy, Zolgensma. The data comes from an ongoing two-year, phase 4 open-label study. Analysts from William Blair suggest that the results indicate the added benefit of Spinraza treatment and predict that it will remain a significant contributor to Biogen's revenues, as well as those of its development partner, Ionis Pharmaceuticals Inc.
July 03, 2023 | 12:36 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
The new Spinraza data could potentially impact Novartis negatively, as it shows improved results in patients previously treated with Novartis' Zolgensma.
The new data shows that Spinraza can improve results in patients who had previously been treated with Novartis' Zolgensma. This could potentially lead to a decrease in sales of Zolgensma, negatively impacting Novartis' revenues and stock price.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
The new data on Spinraza could boost Biogen's revenues and its stock price.
The positive data on Spinraza, a drug developed by Biogen, could lead to increased sales and revenues for the company, which could in turn boost its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
As a development partner of Biogen, Ionis Pharmaceuticals could also benefit from the positive Spinraza data.
Ionis Pharmaceuticals, as a development partner of Biogen, could also see a boost in its revenues and stock price due to the positive data on Spinraza.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80